Hashishi

http://www.guardian.co.uk/business/s...366371,00.html

Looks like the drug regulation boards advised GW to focus their trials on the drug's ability to reduce muscle spasms in MS sufferers...and then told them that the trials weren't concrete enough to justify anything.

"...it decided to choose one particular clinical trial to put in front of the regulators, which tested the drug's reduction of muscle spasms. This is hard to measure objectively, but GW said it focused on this because it was advised to by UK regulators. The CSM told GW that that the data might not be 'clinically relevant'."

All the other trials GW Pharmaceuticals conducted support the drug's effectiveness, so why are they focusing on such a circumstantial one?

This all comes a week before Home Office and Department of Health MPs meet to discuss concerns that MS sufferers are buying cannabis off the street...:GOD FORBID:...and the company is looking to them to sell it unlicensed. In other words, without the support of regulatory entities like the CSM, which was founded in light of the thalidomide ****up.

There have been talks on making the organisation more 'transparent'. God knows what that means though.

It all comes to the sloathful British approach to medicine and pretty much anything else, although I do not question political motivations in Sativex's rejection. Looks like the rest of the world will benefit from the research long before we will here.

__________________